aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Glyphic Biotechnologies, founded with the mission to revolutionize proteomics, focuses on advancing protein sequencing technology. The company aims to provide innovative solutions that enhance the understanding of protein structures and functions, thereby driving progress in biological research and medical diagnostics. Glyphic's core service is its cutting-edge protein sequencing technology, which targets researchers and organizations in the biotechnology and pharmaceutical industries.
Notable figures affiliated with Glyphic Biotechnologies include leading experts in proteomics and biotechnology. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid growth and development. Key achievements include significant advancements in protein sequencing accuracy and efficiency, positioning Glyphic as a leader in the field. The overall impact of Glyphic Biotechnologies lies in its potential to transform proteomics research, leading to breakthroughs in disease understanding and drug development.
Operating Status
Active
Ownership Type(s)
Private
Main Product(s)
Protein Sequencing
Technology
Analytics
Tags
Biotech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Glyphic Biotechnologies founded?
Glyphic Biotechnologies was founded in 2021.
Where is Glyphic Biotechnologies’s headquarters located?
Glyphic Biotechnologies’s headquarters is located in New York City, NY, US.
When was Glyphic Biotechnologies’s last funding round?
Glyphic Biotechnologies’s most recent funding round was for $408.9k (USD) in September 2023.
How many employees does Glyphic Biotechnologies have?
Glyphic Biotechnologies has 25 employees as of Feb 4, 2024.
How much has Glyphic Biotechnologies raised to-date?
As of July 05, 2023, Glyphic Biotechnologies has raised a total of $10.6M (USD) since Sep 14, 2023.
Add Comparison
Total Raised to Date
$10.6M
USD
Last Update Sep 14, 2023
Last Deal Details
$408.9k
USD
Sep 14, 2023
Grant
Total Employees Over Time
25
As of Feb 2024
Glyphic Biotechnologies Address
New York City,
New York
11217
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts